Consolidated sales for the 1st quarter grew by 13% to EUR 63.3 million(up 15% in 2009). Foreign exchange effects were positive by EUR 0.3 million.
This growth confirms the supremacy of SLIT over SCIT, respectivelyposting growth of 17% and a decline of 8% over the 1st quarter. SLIT nowaccounts for 87% of the laboratory's sales.
The analysis by geographic region highlights satisfactory growth in allmarkets, with the "Other EU countries" region continuing to drive Groupgrowth under the effect of the significant increase in Oralair(R) sales inGermany.
Changes in financial position and significant transactions and events ofthe quarter
The financial position improved: cash net of debt was largely positive at31 March, whereas it was negative at the same time last year.
Preliminary results of the Oralair(R) grasses trial in the US should beobtained and released before the end of April.
Outlook for the current financial year
The good first quarter results confirmed the guidance for full-year salesgrowth in excess of 8%, featuring further improvement in profit margins.
Stallergenes is a European biopharmaceutical laboratory specialising intreatments by immunotherapy for the prevention and treatment ofallergy-related respiratory conditions, such as rhino conjunctivitis,rhinitis and allergic asthma. Stallergenes is ranked seventh among Frenchpharmaceutical laboratories. A pioneer and a leader in immunotherapytreatments by sublingual administration, Stallergenes dedicates more than 20%(gross) of its sales to its Research and Development activities, which areprimarily directed at developing a new therapeutic range enabling theprovision of immunotherapy treatments by sublingual tablets.
Stallergenes realised 2009 sales of EUR 193 million, with over 500,000patients treated with Stallergenes desensitisation products.
For further financial information, please visit our website:http://www.stallergenes.comANTONY, France, April 15, 2010 /PRNewswire-FirstCall/ -- EURm 2009 09/08 2010 10/09 EURm %Sales Var.% EURm %Sales Var.% Southern Europe 41.8 74 10 46.9 74 12 (1) Other EU countries 12.7 23 36 14.6 23 15 Other markets 1.7 3 0 1.8 3 8 SLIT 47.2 84 16 55.0 87 17 SCIT 6.9 12 11 6.3 10 (8) Other products 2.1 4 11 2.0 3 (6) Total Q1 sales 56.2 100 15 63.3 100 13